Advertisement

Digestive Diseases and Sciences

, Volume 49, Issue 11–12, pp 1966–1970 | Cite as

Case Report: Severe Interstitial Pneumonitis Secondary to Pegylated Interferon α-2b and Ribavirin Treatment of Hepatitis C Infection

  • Valentin Fuhrmann
  • Ludwig Kramer
  • Edith Bauer
  • Hermann Laferl
  • Gerhard Tucek
  • Gerhard Dekan
  • Peter SchenkEmail author
Article
peginterferon α ribavirin hepatitis C interstitial pneumonitis pulmonary toxicity side effect 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S, Hepatitis C Intervention Therapy Group: Pegylated interferon-α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 68:556–567, 2000CrossRefPubMedGoogle Scholar
  2. 2.
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling MH, Albrecht JK, International Hepatitis Interventional Therapy Group: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358:958–965, 2001CrossRefGoogle Scholar
  3. 3.
    Sonnenblick M, Rosin AJ: Cardiotoxicity of interferon: A review of 44 cases. Chest 99:557–561, 1991CrossRefPubMedGoogle Scholar
  4. 4.
    Conlon KC, Urba WJ, Smith JW2nd, Steis RG, Longo DL, Clark JW: Exacerbation of symptoms of autoimmune disease in patients receiving alphainterferon therapy. Cancer 65:2237–2242, 1990CrossRefPubMedGoogle Scholar
  5. 5.
    Chin K, Tabata C, Sataka N, Nagai S, Moriyasu F, Kuno K: Pneumonitis associated with natural and recombinant Interferon Alfa therapy for chronic hepatitis C. Chest 105:939–941, 1994CrossRefPubMedGoogle Scholar
  6. 6.
    Ishizaki T, Sasaki F, Ameshima S, Shiozaki K, Takahashi H, Abe Y, Ito S, Kuriyama M, Nakai T, Kitagawa M: Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis. Eur Respir J 9:2691–2696, 1996CrossRefPubMedGoogle Scholar
  7. 7.
    Abi-Nassif S, Mark EJ, Fogel RB, Hallisey RK: Pegylated interferon and ribavirin induced interstitial pneumonitis with ARDS. Chest 124:406–410, 2003.CrossRefPubMedGoogle Scholar
  8. 8.
    Ogata K, Koga T, Yagawa K: Interferon-related bronchiolitis obliterans organizing pneumonia. Chest 106:612–613, 1994CrossRefPubMedGoogle Scholar
  9. 9.
    Tahan V, Ozseker F, Guneylioglu D, Baran A, Ozaras R, Mert A, Ucisik AC, Cagatay T, Yilmazabayhan D, Senturk H: Sarcoidosis after use of interferon for chronic hepatitis C. Dig Dis Sci 48:169–173, 2003CrossRefPubMedGoogle Scholar
  10. 10.
    Bini EJ, Weinshel EH: Severe exacerbation of Asthma: A new side effect of interferon-α in patients with Asthma and chronic hepatitis C. Mayo Clin Proc 74:367–370, 1994CrossRefGoogle Scholar
  11. 11.
    Bedossa P, Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The META VIR Cooperative Study Group. Hepatology 24:289–293, 1996CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, Rassam S, Fryden A, Reesink H, Bassendine M, Norkrans G, Cuypers T, Lelie N, Telfer P, Watson J, Weegink C, Sillikens P, Weiland O: Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo controlled study. J Hepatol 25:591–598, 1996CrossRefPubMedGoogle Scholar
  13. 13.
    Abbas AK, Lichtman AH, Pober JS (eds): Effector mechanism of immune responses. In: Cellular and Molecular Immunology. Philadelphia, Saunders, pp 235–335, 2000Google Scholar
  14. 14.
    Ueda T, Ohta K, Suzuki N, Yamaguchi M, Hirai K, Horiuchi T, Watanabe J, Miyamoto T, Ito K: Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. Am Rev Respir Dis 146:266–268, 1992CrossRefPubMedGoogle Scholar
  15. 15.
    Irving WL, Day S, Johnston ID: Idiopathic pulmonary fibrosis and hepatitis C virus infection. Am Rev Respir Dis 148:1683–1684, 1993CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2004

Authors and Affiliations

  • Valentin Fuhrmann
    • 1
  • Ludwig Kramer
    • 1
  • Edith Bauer
    • 1
  • Hermann Laferl
    • 2
  • Gerhard Tucek
    • 3
  • Gerhard Dekan
    • 4
  • Peter Schenk
    • 1
    Email author
  1. 1.Department of Internal Medicine 4, Intensive Care UnitGeneral Hospital and University of ViennaViennaAustria
  2. 2.Department of Internal Medicine 4Kaiser Franz Josef SpitalAustria
  3. 3.Department of PathologyKaiser Franz Josef SpitalAustria
  4. 4.Department of PathologyGeneral Hospital and University of ViennaAustria

Personalised recommendations